A real-world experience with ranibizumab 0.5 mg initial intensive treatment for diabetic macular edema: 24-week outcomes of the RISING-K study
Initial intensive treatment with ranibizumab 0.5 mg was effective in both treatment-naïve and prior-treated patients with DME. Functional outcomes varied by prior anti-VEGF treatment and fluid compartment.
Authors
- Han Joo Cho (ORCID: https://orcid.org/0000-0001-7336-5762)
- Kunho Bae
- Jeong Hun Bae
- Junyeop Lee (ORCID: https://orcid.org/0000-0001-5887-8033)
- In Young Chung (ORCID: https://orcid.org/0000-0003-0671-244X)
- Seung-Young Yu
- Yong-Sok Ji
- Hyewon Chung
- Jihyun Park
- Jae Yon Won
- Younghoon Lee
- Na-Kyung Ryoo
Institutions
- Ulsan College (KR)
- Kyung Hee Cyber University (KR)
- Gyeongsang National University (KR)
- Asan Medical Center (KR)
- Seoul National University Hospital (KR)
- Kyung Hee University (KR)
- University of Ulsan (KR)
- Konkuk University Medical Center (KR)
- St. Mary's Hospital (US)
- Chonnam National University Hospital (KR)
- Novartis (South Korea) (KR)
- Veterans Health Service Medical Center (KR)
- Kim's Eye Hospital (KR)
- Nune Eye Hospital (KR)
- St. Mary's Hospital (US)
- Onnuri Smile Eye Clinic (KR)
Publication Details
- Journal
- Journal of Diabetes and its Complications
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1016/j.jdiacomp.2025.109251
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00